security trading policy, page-31

strange things can happen to stocks that appear marooned for extended periods.

We have had a year of expecting approval, and I think it is fair to say anyone considering buying in to the current level of risk has had more than enough chance to do it. We are a loss making biotech right now, we will be a profit making producer on the other side. That's like an exploration company verses a miner, very different things. I would not be the least bit surprised to see $1 within a week of approval, and $1.50 after sales figures, presuming they are in line with expectations.

I should point out, for the benefit of the Gavel and perhaps others, I am not known for ramping, and am pretty pessimistic generally about anything with 2 outcomes. I think this outcome is probable based on all the information that we have at hand.

A note especially for you Gavel, when you were listing your reasons ACL is a dog, you intentionally included examples of things you know to be erroneous, such as a competitor being allowed to get first jump advantage. What has me intrigued is why?